Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* GCS \< 14 or a NIHSS \> or equal to 6~* Spontaneous supratentorial ICH \> or equal to 20cc~* Symptoms less than 12 hours prior to diagnostic CT scan (an unknown time of symptom onset is exclusionary)~* Intention to initiate surgery within 48 hours after diagnostic CT~* First dose can be given within 54 hours after diagnostic CT (delays for post surgical stabilization of catheter bleeding or because of unanticipated surgical delay are acceptable with approved waiver from the coordinating center) (Does not apply to ICES Tier)~* Six-hour clot size equal to the most previous clot size + 5 cc (as determined by an additional CT scan at least 6 hours after the initial stability scan (A\*B\*C)/2 method)~* SBP \< 200 mmHg sustained for 6 hours recorded closest to time of randomization~* Historical Rankin score of 0 or 1~* Negative pregnancy test~Exclusion Criteria:~* Infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy)~* Patients with platelet count \< 100,000, INR \> 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization~* Clotting disorders~* Any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease~* Patients with a mechanical valve~* Patients with unstable mass or evolving intracranial compartment syndrome~* Ruptured aneurysm, AVM, vascular anomaly~* Greater than 80 years (higher incidence of amyloid)~* Under 18 years of ag e (high incidence of occult vascular malformation)~* Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state)~* Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4~* Historical Rankin score greater than or equal to 2~* Intraventricular hemorrhage requiring external ventricular drainage~* Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts (Does not apply to ICES Tier)~* Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or site of recent surgical intervention (Does not apply to ICES Tier)~* Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, and subacute bacterial endocarditis (Does not apply to ICES Tier)~* In the investigator's opinion, the patient is unstable and would benefit from a specific intervention rather than supportive care plus or minus MIS+rtPA~* Prior enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous trial of ICH treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Medical Management (Type: NO_INTERVENTION): Standard of care medical management as per American Heart Association (AHA) guidelines.
- MISTIE Surgical Management (Type: ACTIVE_COMPARATOR): Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.~This includes 54 intent-to-treat patients, and excludes 27 pilots.
- ICES Surgical Management (Type: ACTIVE_COMPARATOR): Intraoperative stereotactic CT-Guided Endoscopic Surgery~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.~This includes 14 intent-to-treat patients, and excludes 4 pilots.

Based on this trial design, predict the completion outcome and termination type (if applicable).